Skip to content

Effects of Coenzyme Q10 Supplementation on migraine headaches in Patients with Multiple Sclerosis

Effects of Coenzyme Q10 Supplementation on migraine headaches in Patients with Multiple Sclerosis: A Randomized Double-Blinded Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250107064304N1
Enrollment
40
Registered
2025-04-10
Start date
2025-04-21
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache.

Interventions

Intervention 1: Intervention group: The study duration was designed for 4 months, which included a one-month run-in period and a three-month treatment trial phase with CoQ10. During the run-in period

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with MS according to the 2017 McDonald criteria who refer to the MS clinic of Kashani Hospital, Isfahan, will be screened in 2025 With headache complaints and migraine diagnosis based on the ICHD-3: The International Classification of Headache Disorders Age 18-50 years

Exclusion criteria

Exclusion criteria: The presence of any other disorder or disease that causes secondary headache (hypothyroidism, anemia, hypercapnia, chronic uncontrolled blood pressure, etc.) Patients who have had a long history of chronic headaches before developing MS Taking CoQ10 or other antioxidant supplements within the past 3 months Taking medications, including contraceptives, vasodilators, nitrates, and any medication that increases migraine headaches Pregnancy, breastfeeding and menopause Smoking, NSAID use, or any opioid drugs History of stroke, heart attack, and psychiatric illness Stages of disability so severe that the patient is unable to cooperate in taking a detailed history MS relapse within 30 days of starting medication Any type of allergic reaction after taking the drug The patient's unwillingness to continue participating in the study or their lack of cooperation in taking the medication on time

Design outcomes

Primary

MeasureTime frame
Severity and number of headache attacks. Timepoint: At the start of the study and after one month of treatment. Method of measurement: HIT-6 questionnaire.

Secondary

MeasureTime frame
Depression. Timepoint: When starting after one month of treatment. Method of measurement: Beck score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Shokrani Foroshani

Esfahan University of Medical Sciences

rezashokrani128@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026